Loading data for UPB — first visit, this takes a few seconds.
Upstream Bio Inc. (UPB)
NasdaqGS: UPB
· Real-Time Price · USD
6.69
-0.10 (-1.47%)
At close: Aug 28, 2026, 8:00 PM
6.69
+0.00%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
Upstream Bio Inc. (UPB) Stock Price, Analysis & Data
-1.47% (1D)
No data available
| Bid | 4.84 |
| Market Cap | 366.42M |
| Revenue (ttm) | 3.16M |
| Net Income (ttm) | -156.5M |
| n/a | |
| -2.84 | |
| n/a | |
| -2.28 | |
| P/B (ttm) | 1.20 |
| P/S (ttm) | 116.03 |
| Earnings Date | Nov 4, 2026 |
| Ask | 8.51 |
| Volume | 445,475 |
| Avg. Volume (20D) | 608,393 |
| Open | 6.71 |
| Previous Close | 6.79 |
| Day's Range | 6.60 - 6.79 |
| 52-Week Range | 5.85 - 33.68 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About UPB
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headqu...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 11, 2024
Employees 75
Stock Exchange NasdaqGS
Ticker Symbol UPB
Website https://upstreambio.com
Financial Performance
In 2025, Upstream Bio's revenue was 2.85M, an increase of 20.42% compared to the previous year's 2.37M. Earnings were -143.44M, an increase of 128.39%.
Financial StatementsEarnings Surprise
Upstream Bio has released their quarterly earnings on Aug 11, 2026:
- Revenue of $1.03M misses estimates by $0, with 82.69% YoY growth.
- EPS of -0.73 exceeds estimates by 0.03, with 1.35% YoY growth.
Upstream Bio Inc. is scheduled to release its earnings on Nov 4, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2